Contact Information: Company Contact: Delcath Systems, Inc. Richard Taney (212) 489-2100 Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper/Cass Almendral (212) 838-1444 Public Relations Contact: Rubenstein Associates, Inc. Robin Wagge (212) 843-8006
Delcath Systems to Host Quarterly Update Conference Call
| Source: Delcath Systems, Inc.
NEW YORK, NY--(Marketwire - August 28, 2008) - Delcath Systems, Inc. (NASDAQ : DCTH ) announced
today that the Company will host a quarterly update conference call.
Richard Taney, President and Chief Executive Officer of Delcath Systems,
will host the call beginning at 4:30 pm Eastern Time on Wednesday,
September 10, 2008. During the call, Mr. Taney will discuss recent progress
made regarding the rollout of clinical studies and the Company's ongoing
strategy for increasing the enrollment program over the near term. A
question and answer session will immediately follow management's prepared
remarks.
The conference call will be webcast and may be accessed by visiting Delcath
Systems' website at www.delcath.com. A replay of the audio webcast will be
available on the Company's website starting shortly after the call on
September 10, 2008.
Those parties interested in participating in the live call may join by
dialing (304) 345-7506 in the U.S. and referencing conference
identification number 279838. A telephone replay will be available at 7:30
pm EDT the day of the live call and can be accessed by dialing
(402)970-2661 in the U.S and referencing conference identification number
100539. The replay will be available until Wednesday, September 24, 2008
until 7:30 pm EDT.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in
cancer treatment. The Company has developed a proprietary, patented system
which will improve the efficacy of cancer treatment while reducing the
considerable, systemic side-effects of chemotherapy. Delcath's novel drug
delivery platform is capable of delivering anti-cancer drugs at very high
doses to a specific organ or region of the body while preventing these high
doses of drug from entering the patient's bloodstream. The Company is
currently enrolling patients in Phase III and Phase II clinical studies for
the treatment of liver cancers using high doses of melphalan. The
Company's intellectual property portfolio consists of twenty-eight patents
on a worldwide basis including the U.S., Europe, Asia and Canada. For more
information, please visit the Company's website at www.delcath.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by the Company or on its behalf. This
news release contains forward-looking statements, which are subject to
certain risks and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such differences
include, but are not limited to, uncertainties relating to our ability to
successfully complete Phase III clinical trials and secure regulatory
approval of our current or future drug-delivery system and uncertainties
regarding our ability to obtain financial and other resources for any
research, development and commercialization activities. These factors, and
others, are discussed from time to time in our filings with the Securities
and Exchange Commission. You should not place undue reliance on these
forward-looking statements, which speak only as of the date they are made.
We undertake no obligation to publicly update or revise these
forward-looking statements to reflect events or circumstances after the
date they are made.